Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

PALYNZIQ

PEGVALIASE-PQPZ

Standard Dose
10MG/0.5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview PALYNZIQ is listed in Drugs@FDA under application 761079 (BLA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient PEGVALIASE-PQPZ Form and strength INJECTABLE;INJECTION - 10MG/0.5ML Sponsor BIOMARIN PHARM Submission history Latest submission status date: 2026-02-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview PALYNZIQ is listed in Drugs@FDA under application 761079 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient PEGVALIASE-PQPZ Form and strength INJECTABLE;INJECTION - 10MG/0.5ML Sponsor BIOMARIN PHARM Submission history Latest submission status date: 2026-02-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.